drug
(dolutegravir sodium + lamivudine)
Marketedupdated 3mo agoby ViiV Healthcare Company
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying (dolutegravir sodium + lamivudine)
- phase3Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
- phase2Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
- phase4Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
- phase1A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 5, 2027
230 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Jan 24, 2031formulationUS 112349854.4y
- Jun 8, 2030patentUS 9242986*PED3.8y
- Dec 8, 2029compositionUS 92429863.3y
- Apr 5, 2028patentUS 8129385*PED1.6y
- Oct 5, 2027compositionUS 81293851.1y
FDA exclusivities (1)
- Apr 5, 2027NPPNew Product (3y)230d
News(1)
- GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardGSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…fiercebiotech · 20d ago
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that